Treatment of Cryptogenic New-onset Refractory Status Epilepticus (C-NORSE) with Tocilizumab

Yumiko Nakamura; Masayuki Ueda; Satoshi Kodama; Tomohiko Kimura; Yuichiro Shirota; Masashi Hamada; Hiroyuki Ishiura; Takahiro Iizuka; Tatsushi Toda

doi:10.2169/internalmedicine.3392-23

Back

$Treatment of Cryptogenic New-onset Refractory Status Epilepticus (C-NORSE) with Tocilizumab$

Journal article

Open access

Peer reviewed

Treatment of Cryptogenic New-onset Refractory Status Epilepticus (C-NORSE) with Tocilizumab

Yumiko Nakamura, Masayuki Ueda, Satoshi Kodama, Tomohiko Kimura, Yuichiro Shirota, Masashi Hamada, Hiroyuki Ishiura, Takahiro Iizuka and Tatsushi Toda

Internal medicine (Tokyo, 1992), Vol.63(24), pp.3377-3382

12/15/2024

DOI: 10.2169/internalmedicine.3392-23

PMID: 38658340

Files and links (1)

url

https://doi.org/10.2169/internalmedicine.3392-23View

Published (Version of record) Open Access

Abstract

A 35-year-old woman with no prior history of epilepsy developed status epilepticus (SE), which was highly resistant to multiple antiseizure medications and sedatives. The etiology of SE was not identified despite extensive investigation, and the patient was diagnosed with cryptogenic new-onset refractory status epilepticus (C-NORSE). Although first-line immunotherapies such as high-dose corticosteroids and plasma exchange were ineffective, the patient manifested a resolution of SE after the administration of tocilizumab, which inhibits interleukin-6. Non-antibody-mediated inflammation has been hypothesized to be a probable pathophysiology of C-NORSE in recent studies, and tocilizumab may be a plausible second-line treatment.

Adult

Antibodies, Monoclonal, Humanized - therapeutic use

Anticonvulsants - therapeutic use

Female

Humans

Interleukin-6 - antagonists & inhibitors

Interleukin-6 - blood

Status Epilepticus - diagnosis

Status Epilepticus - drug therapy

Status Epilepticus - etiology

Treatment Outcome

Details

Title: Subtitle: Treatment of Cryptogenic New-onset Refractory Status Epilepticus (C-NORSE) with Tocilizumab
Creators: Yumiko Nakamura - The University of Tokyo
Masayuki Ueda - The University of Tokyo
Satoshi Kodama - The University of Tokyo
Tomohiko Kimura - The University of Tokyo
Yuichiro Shirota - The University of Tokyo
Masashi Hamada - The University of Tokyo
Hiroyuki Ishiura - The University of Tokyo
Takahiro Iizuka - Kitasato University
Tatsushi Toda - The University of Tokyo
Resource Type: Journal article
Publication Details: Internal medicine (Tokyo, 1992), Vol.63(24), pp.3377-3382
DOI: 10.2169/internalmedicine.3392-23
PMID: 38658340
NLM abbreviation: Intern Med
ISSN: 0918-2918
eISSN: 1349-7235
Language: English
Date published: 12/15/2024
Academic Unit: Neurology
Record Identifier: 9985178662502771

Metrics

2 Record Views

Treatment of Cryptogenic New-onset Refractory Status Epilepticus (C-NORSE) with Tocilizumab

Files and links (1)

Related content

Abstract

Details

Metrics